Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: The data collection on adverse events of Anti-HIV drugs study

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Kovari, Helen ^a   Sabin, Caroline A ^b   Ledergerber, Bruno ^a   Ryom, Lene ^c   Reiss, Peter ^d   Law, Matthew ^e   Pradier, Christian ^f   Dabis, Francois ^g   d'Arminio Monforte, Antonella ^h   Smith, Colette ^b   de Wit, Stephane ⁱ   Kirk, Ole ^c   Lundgren, Jens D ^c   Weber, Rainer ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h SAN PAOLO HOSPITAL   (Italy)

ⁱ SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Alanine aminotransferase; Antiretroviral therapy; Hepatotoxicity; HIV; Liver disease

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EXPOSURE; DYSLIPIDEMIA; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 85000797854     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw009     Document Type: Article

References (42)

1. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS 2011; 6:272-7.
2. Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008; 53:1375-82.
3. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50:502-11.
4. Crum-Cianflone N, Collins G, Medina S, et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol 2010; 8:183-91.
5. Bansi L, Gazzard B, Post F, et al. Biomarkers to monitor safety in people on art and risk of mortality. J Acquir Immune Defic Syndr 2012; 60:51-8.
6. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIVinfected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-6.
7. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-92.
8. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-72.
9. Merchante N, Perez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15:753-63.
10. Ryom L, Lundgren JD, De Wit S, et al. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016 Jan 8. PMID 26752282.
11. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626-35.
12. Sabin CA, Ryom L, Kovari H, et al. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D Study. J Acquir Immune Defic Syndr 2013; 63:456-63.
13. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-42.
14. Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-Monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis 2015; 60:1569-78.
15. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
16. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-23.
17. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
19. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-55.
20. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59:342-6.
21. Lattuada E, Lanzafame M, Carolo G, et al. Does tenofovir increase efavirenz hepatotoxicity? AIDS 2008; 22:995.
22. Qayyum S, Dong H, Kovacic D, et al. Combination therapy efavirenz/emtricitabine/ tenofovir disoproxil fumarate associated with hepatic failure. Curr Drug Saf 2012; 7:391-3.
23. Fink DL, Bloch E. Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring. Int J STD AIDS 2013; 24:831-3.
24. Echenique IA, Rich JD. EFV/FTC/TDF-associated hepatotoxicity: a case report and review. AIDS Patient Care STDS 2013; 27:493-7.
25. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
26. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-9.
27. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
28. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-201.
29. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-23.
30. Adaramoye OA, Adewumi OM, Adesanoye OA, et al. Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E. J Basic Clin Physiol Pharmacol 2012; 23:69-75.
31. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-6.
32. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005; 45:1360-7.
33. Rotger M, Colombo S, Furrer H, et al. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther 2007; 12:115-8.
34. Lapadula G, Costarelli S, Chatenoud L, et al. Risk of liver enzyme elevation during treatment with ritonavir-boosted protease inhibitors among HIV-monoinfected and HIV/HCV coinfected patients. J Acquir Immune Defic Syndr 2015; 69:312-8.
35. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009; 37:244-9.
36. Rodriguez JM, Hermida JM, Casado JL, et al. The use of atazanavir in HIVinfected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. AIDS 2011; 25:1006-9.
37. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-95.
38. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:464-73.
39. Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15:323-30.
40. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drug-related liver mortality amongHIV-positive persons in the absence of hepatitisBorCvirus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis 2013; 56:870-9.
41. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gammaglutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136:477-85.e11.
42. Lee TH, Kim WR, Benson JT, et al. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008; 47:880-7.